HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 26, Nos. 07 & 08, July & August 2022 – Engineering a Sustainable Future       » Improving Crop Yield With Leaf Angles       » Combatting Tumours at the Gut With Novel Oral Vaccine Made by Bacteria Robot       » New Carbon Capture System With Record-Breaking Efficiency to Revolutionise Direct Air Capture       » Simulating the Synergistic Interactions of Neurons and Synapses in Computing Devices       » Understanding Gene Functions: From Algae to Plants       » Colour-Modified Mice Tissues Allow for Higher-Resolution Imaging      
Vol 26, Nos. 07 & 08, July & August 2022   |   Issue PDF view/purchase
EYE ON CHINA
Discovery of Novel Non-Statin-Based Cholesterol-Lowering Compound
The new compound exhibits a good safety profile and tolerability among individuals, providing an effective alternative for patients with statin intolerance.

Hyperlipidaemia, or a high level of lipids (fats) in the blood, is a major risk factor for atherosclerosis and coronary artery disease. Currently, lipid-lowering agents like statins are the main clinical treatment for hyperlipidaemia. While generally effective, the same cannot be said for about one-fifth of the patients with high levels of cholesterols or who have statin intolerance.

As the consumption of processed foods increases, as well as leading a sedentary lifestyle, cardio-metabolic diseases like hyperlipidaemias are also set to rise. Hence, developing non-statin-based cholesterol-lowering small compounds would be highly desirable.

In a study published in Cell Metabolism, a group of scientists from the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences found a novel target for hyperlipidaemia and developed a novel lipid-lowering small compound DC371739, which exhibited a promising lipid-lowering effect in vitro and in vivo, as well as a good safety profile and tolerability in both healthy subjects and patients with hyperlipidaemia.

Their novel compound was derived from tetrahydroprotoberberines (THPBs) that were extracted from the Chinese herb Corydalis ambigua, which had previously demonstrated various biological activities. In previous works, they had made chemical modifications to THPBs and constructed a small compound library with different scaffolds. They then screened this library for hyperlipidaemic drug candidates and performed structure-activity relationship and drug-like property evaluation to identify their novel highly potent DC371739.

The team proved that the novel compound effectively reduced the total cholesterol and low-density lipoprotein (or “bad”) cholesterol in the serum of hyperlipidaemic hamsters and rhesus monkeys in a dose-dependent manner.

When compared to other lipid-lowering agents like berberine, DC371739 acts in a distinct manner. While oral administration of berberine can reduce serum total cholesterol and bad cholesterol in patients after three months of treatment, it requires a high oral dose, has poor bioavailability, and there is a potential for hERG potassium channel inhibitory activity. The team’s novel compound, on the other hand, displayed higher bioavailability than berberine and lower inhibition of hERG channel in vitro.

Furthermore, the team went on to combine the treatment of DC371739 with atorvastatin and found that the dual therapy promoted more lipid-lowering effects than either monotherapy, thus providing a potential therapeutic strategy for patients with atorvastatin intolerance.


Source: Wang et al. (2022). Identification and evaluation of a lipid-lowering small compound in preclinical models and in a Phase I trial.Cell Metabolism,34(5), 667-680.

FORTHCOMING ISSUE  
MGI Makes Possible New Advances in Agrigenomics Research and Molecular Breeding
NEWS CRUNCH  
news 2022 PDA Pharmaceutical Manufacturing & Quality Conference
news Medtec China 2022 Gathers Medtech Leading Enterprises, Optimising Medical Equipment Supply Chain by Creating Online-Offline Promotion Platforms
news Medtec China 2022 Is Now Open for Visitor Registration, Helping Medical Device Manufacturers in Medtech Sourcing and Supply Chain Stabilisation
news Inaugural Asia Summit on Global Health highlights Hong Kong's advantages
SPOTLIGHT  

MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Contribute to APBN
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   [email protected] or Ms Carmen Chan
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   [email protected]
Copyright© 2022 World Scientific Publishing Co Pte Ltd  •  Privacy Policy